Measurement of Peak C-Peptide at Diagnosis Informs Glycemic Control but not Hypoglycemia in Adults With Type 1 Diabetes.
C-peptide
CGM
hypoglycemia
type 1 diabetes
Journal
Journal of the Endocrine Society
ISSN: 2472-1972
Titre abrégé: J Endocr Soc
Pays: United States
ID NLM: 101697997
Informations de publication
Date de publication:
01 Oct 2021
01 Oct 2021
Historique:
received:
04
05
2021
entrez:
11
8
2021
pubmed:
12
8
2021
medline:
12
8
2021
Statut:
epublish
Résumé
High-residual C-peptide in longer-duration type 1 diabetes (T1D) is associated with fewer hypoglycemic events and reduced glycemic variability. Little is known about the impact of C-peptide close to diagnosis. Using continuous glucose monitoring (CGM) data from a study of newly diagnosed adults with T1D, we aimed to explore if variation in C-peptide close to diagnosis influenced glycemic variability and risk of hypoglycemia. We studied newly diagnosed adults with T1D who wore a Dexcom G4 CGM for 7 days as part of the Exercise in Type 1 Diabetes (EXTOD) study. We examined the relationship between peak stimulated C-peptide and glycemic metrics of variability and hypoglycemia for 36 CGM traces from 23 participants. For every 100 pmol/L-increase in peak C-peptide, the percentage of time spent in the range 3.9 to 10 mmol/L increased by 2.4% (95% CI, 0.5-4.3), C-peptide is associated with time spent in the normal glucose range and with less hyperglycemia, but not risk of hypoglycemia in newly diagnosed people with T1D.
Identifiants
pubmed: 34377883
doi: 10.1210/jendso/bvab127
pii: bvab127
pmc: PMC8344843
doi:
Types de publication
Journal Article
Langues
eng
Pagination
bvab127Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society.
Références
Diabet Med. 2017 Nov;34(11):1521-1531
pubmed: 28905421
Diabetologia. 2015 Jun;58(6):1167-74
pubmed: 25773405
BMJ Open. 2015 Nov 02;5(11):e009088
pubmed: 26525723
Diabetes. 2012 Aug;61(8):2066-73
pubmed: 22688329
Diabetes. 2004 Jan;53(1):250-64
pubmed: 14693724
Diabetologia. 2020 May;63(5):906-914
pubmed: 32034440
Diabetes Obes Metab. 2014 Mar;16(3):262-7
pubmed: 24118704
Diabet Med. 2019 Sep;36(9):1092-1099
pubmed: 30955221
Diabetes Care. 2021 Feb;44(2):390-398
pubmed: 33303639
Diabetologia. 2012 Dec;55(12):3359-68
pubmed: 22990715
Diabetes Care. 2015 Mar;38(3):476-81
pubmed: 25519448
Diabetes Care. 2014;37(1):39-43
pubmed: 24356596
Diabetes Care. 2003 Mar;26(3):832-6
pubmed: 12610045
J Clin Invest. 2021 Feb 1;131(3):
pubmed: 33529168
J Clin Invest. 2020 Apr 1;130(4):1850-1862
pubmed: 31895699
Diabetes Technol Ther. 2001 Spring;3(1):81-90
pubmed: 11469711
Ann Intern Med. 1998 Apr 1;128(7):517-23
pubmed: 9518395
Diabetes Care. 2016 Mar;39(3):337-44
pubmed: 26577414
Diabetes Care. 2017 Jul;40(7):832-838
pubmed: 28039172
N Engl J Med. 2002 May 30;346(22):1692-8
pubmed: 12037148
Trials. 2013 Jun 18;14:180
pubmed: 23777480
J Clin Endocrinol Metab. 2012 Nov;97(11):E2078-83
pubmed: 22996144
Diabetes Care. 2017 Dec;40(12):1631-1640
pubmed: 29162583
Diabetes Care. 2009 Aug;32(8):1384-90
pubmed: 19435955
Diabetes Care. 2018 Jul;41(7):1486-1492
pubmed: 29880650
Diabetes Technol Ther. 2009 Jun;11 Suppl 1:S11-6
pubmed: 19469670
Diabetes. 2003 Nov;52(11):2790-4
pubmed: 14578298
Diabetes Care. 2015 Jan;38(1):105-12
pubmed: 25422169
Diabetes Metab Res Rev. 2009 May;25(4):325-8
pubmed: 19267337
Diabet Med. 2014 Oct;31(10):1264-8
pubmed: 24836354
PLoS One. 2012;7(7):e42084
pubmed: 22860060